KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Restructuring Costs (2022 - 2025)

Pacira BioSciences (PCRX) has 3 years of Restructuring Costs data on record, last reported at $851000.0 in Q4 2025.

  • For Q4 2025, Restructuring Costs fell 82.38% year-over-year to $851000.0; the TTM value through Dec 2025 reached $14.1 million, up 83.23%, while the annual FY2025 figure was $14.1 million, 83.23% up from the prior year.
  • Restructuring Costs reached $851000.0 in Q4 2025 per PCRX's latest filing, down from $6.8 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $6.8 million in Q3 2025 and bottomed at -$1.8 million in Q3 2024.
  • Average Restructuring Costs over 3 years is $1.9 million, with a median of $900000.0 recorded in 2023.
  • Peak YoY movement for Restructuring Costs: tumbled 1120.81% in 2024, then skyrocketed 484.54% in 2025.
  • A 3-year view of Restructuring Costs shows it stood at -$1.5 million in 2023, then soared by 430.6% to $4.8 million in 2024, then tumbled by 82.38% to $851000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Restructuring Costs were $851000.0 in Q4 2025, $6.8 million in Q3 2025, and $283000.0 in Q2 2025.